The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.

Disclosed is a compound of formula (I) which is a fatty acid acetylated salicylate derivative, a fatty acid acetylated diflunisal derivative, a fatty acid acetylated triflusal derivative or 3-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidobenzoic acid. Also disclosed are methods of treating non-human animals for inflammation with the compounds and a pharmaceutical composition comprising the compounds. Further disclosed is the use of the compound for the manufacture of a medicament for...

The present invention proposes a stable triflusal compound powder for oral administration solid pharmaceutical forms which contains as a stabilizing excipient at least one cyclodextrin selected from: ²-cyclodextrin ±-cyclodextrin dimethyl-²-cyclodextrin ³-cyclodextrin 2-hydroxyethylcyclodextrin and mixtures thereof. The mentioned triflusal compound powder is used for producing granules tablets or sachets. The mentioned triflusal compound powder is prepared by dry preparation.

The present invention proposes a stable triflusal compound powder for oral administration solid pharmaceutical forms, which contains, as a stabilizing excipient, at least one cyclodextrin selected from: -cyclodextrin, +--cyclodextrin, dimethyl--cyclodextrin, -cyclodextrin, 2-hydroxyethylcyclodextrin, and mixtures thereof. The mentioned triflusal compound powder is used for producing granules, tablets or sachets. The mentioned triflusal compound powder is prepared by dry preparation.

A Medicaments for inhibiting thrombus formation contains active ingredients which are triflusal and clopidogrel bisulfate, wherein a mass ratio of triflusal to clopidogrel bisulfate is (100-650) : (30-150) , preferably (1-20):1, more preferably (3-6): 1, and even more preferably 3:1 or 6:1.

A Medicaments for inhibiting thrombus formation contains active ingredients which are triflusal and clopidogrel bisulfate, wherein a mass ratio of triflusal to clopidogrel bisulfate is (100-650):(30-150), preferably (1-20):1, more preferably (3-6):1, and even more preferably 3:1 or 6:1.